nipradilol has been researched along with Diabetic Retinopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, N; Kanamori, A; Nagai-Kusuhara, A; Nakamura, M; Nakanishi, Y; Negi, A; Tatsumi, Y | 1 |
| Hakamada, Y; Ito, Y; Kakehashi, A; Kawakami, M; Kitazume, Y; Kobayashi, E; Makino, S; Ono, R; Sugi, N; Takagi, Y | 1 |
2 other study(ies) available for nipradilol and Diabetic Retinopathy
| Article | Year |
|---|---|
Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation in vitro and by diabetes in vivo.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; Calcium; Caspase 3; Cell Line; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP-Dependent Protein Kinases; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dose-Response Relationship, Drug; Glutamic Acid; In Situ Nick-End Labeling; Male; Propanolamines; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Serum; Vasodilator Agents | 2008 |
Effect of topical nipradilol on retinal microvascular leukocyte adhesion in diabetic rats.
Topics: Administration, Topical; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cell Adhesion; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Fluorescein Angiography; Leukocyte Count; Leukocytes; Leukostasis; Microcirculation; Nitric Oxide; Nitric Oxide Donors; Ophthalmic Solutions; Propanolamines; Rats; Rats, Inbred BN; Retinal Artery | 2006 |